Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D gr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Proc Natl Acad Sci U S A
Asıl Yazarlar: Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Smith, Jordan L., Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2015
Konular:
PNAS Plus
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394293/
https://ncbi.nlm.nih.gov/pubmed/25805818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1415569112
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller